What's Going On With Liver Disease Focused Vir Biotechnology Stock Is Friday?
On Friday, Vir Biotechnology, Inc. (NASDAQ:VIR) announced end-of-treatment data from Part B of the MARCH Phase 2 study ...
gulftoday4h
Understanding hepatitis C
Hepatitis C is a viral infection that causes inflammation and damage to the liver, requiring a liver transplant if not ...
Tamil director Suresh Sangaiah succumbs to liver failure: 9 liver cirrhosis symptoms to watch out for
Renowned Tamil filmmaker Suresh Sangaiah passed away in Chennai on Friday, November 15, at the Rajiv Gandhi Hospital, ...
Barinthus Bio Announces Results From Ongoing Phase 2b Chronic Hepatitis B Trial, Including Achievement of Functional Cure and HBsAb Seroconversion
Eight participants achieved HBsAg loss at any time.Two participants met criteria for functional cure. Two participants who ...
manilatimes20h
Arbutus' Imdusiran Achieves Functional Cure in cHBV Patients when Combined with a Short Course of Interferon
50% of patients (3/6) with baseline HBsAg <1000 IU/mL achieved a functional cure (defined as sustained HBsAg loss and HBV DNA ...
Scientists develop novel plug-and-play test to evaluate T cell immunotherapy effectiveness
A novel test developed by Duke-NUS researchers enables real-time monitoring of T cells that have been engineered to fight ...
Medpage Today on MSN21h
Primary Biliary Cholangitis Incidence and Prevalence Growing
Primary biliary cholangitis (PBC) has typically been considered a rare condition, with a pooled global estimated incidence of ...
The Bakersfield Californian21h
Barinthus Bio Announces Results From Ongoing Phase 2b Chronic Hepatitis B Trial, Including ...
Eight participants achieved HBsAg loss at any time.Two participants met criteria for functional cure.Two participants who ...
Precision BioSciences to present preclinical PBGENE-HBV data
Precision BioSciences (DTIL) will present preclinical data supporting the advancement of PBGENE-HBV into clinical development. The company will ...
Arbutus and Barinthus announce new data from IM-PROVE II trial
Arbutus Biopharma (ABUS) and Barinthus Biotherapeutics (BRNS) announced new preliminary data from the Phase 2a IM-PROVE II clinical trial of ...
Arbutus Biopharma Corporation: Arbutus' Imdusiran Achieves Functional Cure in cHBV Patients when Combined with a Short Course of Interferon
HBsAg levels less than 1000 IU/mL achieved functional cure in Cohort A1 of the IM-PROVE I Phase 2a clinical trial Overall, in Cohort A1, 25% of patients achieved functional ...
Le Lézard20h
Gilead's Livdelzi (Seladelpar) Demonstrated a Sustained Efficacy and Long-Term Safety Profile in Management of Primary Biliary Cholangitis
Gilead Sciences, Inc. today announced data from a two-and-a-half-year interim analysis from the ongoing Phase 3 ASSURE study, which showed that 81% (30 out of 37) of participants with primary biliary ...